Amgen's Q2 Beat Looks Strong Until You Check the Balance Sheet

Amgen's second-quarter earnings read like momentum. Total revenues rose 10% to $10.1 billion. Non-GAAP EPS hit $6.29, up 4% from a year ago. Twenty-two products delivered double-digit sales growth. The company raised full-year revenue guidance to $38.2 billion–$39.4 billion and non-GAAP EPS to $22.30–$23.50. The stock rose on the earnings news.

The headline reads like a win. The factor stack tells you whether that momentum is durable or whether valuation has already caught up to the good news. Let's work through it.

Valuation: A Premium That Needs Growth to Defend It

Amgen trades at roughly 25 times trailing earnings. That is above Bristol-Myers Squibb (14x) and below AbbVie (69x). Pfizer sits near 33x, but Pfizer's earnings are currently depressed by pandemic tailwind run-off, so it's a thin comparison. On a forward basis - which matters more because it reflects expected earnings - Amgen's forward P/E is approximately 34.5x.

The PEG ratio (P/E divided by earnings growth rate) is 0.79. A PEG below 1.0 suggests earnings growth is sufficient to justify the multiple. That's doing heavy lifting here. Amgen's revenue growth came in at roughly 9% year-over-year on a trailing basis, but gross profit growth is 17.6%, which tells you margin expansion is accelerating alongside top-line growth. That's the mechanism that lets a 25x P/E look defensible rather than expensive.

The question isn't whether Amgen is the cheapest in its peer set. It's whether it's the best value relative to what it's delivering. The valuation factor passes, but only because the growth and profitability factors are carrying the weight.

Growth: The Six Drivers Are Doing the Heavy Lifting

This is where Amgen earns its premium. The six designated key growth drivers - Repatha, EVENITY, TEZSPIRE, UPLIZNA, Imdelltra, and the biosimilars segment - grew 26% collectively and now represent nearly 70% of product sales. The individual numbers:

• Repatha (cholesterol): +37% to $953M
• EVENITY (osteoporosis): +38% to $714M
• TEZSPIRE (asthma): +42% to $486M
• UPLIZNA (neuromyelitis optica): +90% to $335M
• Imdelltra (small-cell lung cancer): +115%
• Biosimilars segment: +29%

That is portfolio breadth, not concentration. When six unrelated products across different therapeutic areas all grow at once, it means sales infrastructure, pipeline execution, and demand are aligned. You can argue the stock is expensive. You can't argue the operating engine isn't working.

The legacy erosion is the counterpoint. Prolia fell 32% as multiple biosimilars launched globally. Enbrel is down 4%, with a 22% decline in net selling price reflecting IRA Medicare Part D price-setting (effective January 2026) and increased 340B program mix. Otezla fell 21%. The Prolia/XGEVA franchise - still $1.1 billion for the quarter - is the single largest drag. But with 17 products now annualizing above $1 billion based on Q2 sales, legacy decline is manageable rather than existential.

Profitability: Margins Are Expanding

GAAP operating margin jumped 6.5 percentage points to 36.8% in the quarter. Non-GAAP operating margin ticked down 0.5 points to 48.4%, which is the more apples-to-apples comparison since it strips one-time items. Gross margin sits at 68.3% and EBITDA margin at 41.6%. Return on invested capital is 14.9%, solid for biopharma.

Revenue growth is translating into margin expansion, not just top-line movement. The cost structure is scaling efficiently.

Safety: The One Factor That Raises Eyebrows

Total debt stands at $84 billion against total equity of $11.7 billion. The debt-to-equity ratio is roughly 490%. That is extremely high - it means the company is leveraged heavily, and any sustained period of weak cash flow would create balance-sheet stress.

Cash and equivalents are $14 billion. Net debt is $43.3 billion. The current ratio (1.37) and quick ratio (1.13) are adequate for short-term liquidity. Free cash flow for the trailing twelve months is $10.2 billion, with Q2 at $3.5 billion versus $1.9 billion a year ago - though part of that improvement reflects the final repatriation tax payment in Q2 2025, making the prior-year comparison favorable. FCF growth on a YoY TTM basis is actually slightly negative at -4%.

At a $218 billion market cap, Amgen can afford this leverage today. But a 490% debt-to-equity ratio is a structural constraint. It limits M&A capacity, constrains dividend growth (currently ~2.4% yield after 14 consecutive years of increases), and means earnings deterioration would pressure the balance sheet faster than at a more conservatively capitalized peer.

Momentum: Hot, But Not Yet Overheated

The stock sits at roughly $405, well above both the 50-day moving average ($359) and the 200-day moving average ($345). The MACD line is positive at 9.7, confirming upward momentum. RSI is 71.3, which is in overbought territory by standard definitions (70+), but momentum stocks often sustain elevated RSI during earnings-driven repricing. Twenty-day volatility is 2.8%, moderate - the stock isn't whipsawing.

Price action is trailing the fundamental improvement rather than running ahead of it. RSI at 71 is a yellow flag, not a red one. It tells you the stock could consolidate, not that the thesis has broken.

The Counterpoint: One Obesity Card Left

Amgen discontinued AMG 513, a Phase 1 obesity candidate, during the quarter. MariTide remains as Amgen's sole weight-loss program, currently in Phase 3. Executives said the late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities - a quiet admission that in-licensing activity will slow.

MariTide, a Phase 3 obesity candidate, is the last visible card. If it underperforms or faces execution risk, the growth narrative loses its most visible long-term catalyst.

What the Factor Stack Says

• Valuation: passes - the PEG ratio and margin expansion justify the premium, but it isn't cheap.
• Growth: strong - six drivers, 26% aggregate growth, broad-based execution.
• Profitability: strong - expanding margins, 14.9% ROIC.
• Safety: weak - 490% debt-to-equity is a real structural constraint.
• Momentum: positive - price above key moving averages, RSI elevated but sustainable.

The factor stack points to Amgen as a quality-growth name with a balance-sheet caveat. It's not a deep-value play - the multiple reflects what the market already knows about the growth drivers. But the breadth of those drivers, the raised guidance, and the margin trajectory suggest the repricing has room to continue if execution holds.

The triggers that would change the thesis aren't a soft quarter - the pipeline is broad enough that one product won't derail it. They are: (1) a sustained reversal in one of the six growth drivers, particularly Repatha or TEZSPIRE, which carry the largest revenue share; (2) balance-sheet pressure if debt service becomes burdensome in a rate environment that doesn't ease; or (3) MariTide underperforming in Phase 3, which would remove the most visible long-term growth option.

If you're positioning for the second half of 2026, Amgen belongs in the quality-growth sleeve, not the value sleeve. The barbell logic applies: pair it with a high-yield, low-debt name for the downside hedge. The factor stack doesn't say "buy everything." It says this is the stock that keeps running if growth holds - and the debt load is the specific number you need to watch if the cycle turns.